Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 18, 2025 15:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response...
April 18, 2025 11:15 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and...
April 18, 2025 11:15 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : Le Dupixent devient le premier nouveau médicament ciblé approuvé aux États-Unis depuis plus de dix ans pour le traitement de l’urticaire chronique spontanée

Le Dupixent devient le premier nouveau médicament ciblé approuvé aux États-Unis depuis plus de dix ans pour le traitement de l’urticaire chronique spontanée Aux États-Unis, le Dupixent est indiqué à...
April 18, 2025 11:15 ET | Source: Sanofi Winthrop Industrie

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch...
April 18, 2025 08:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse - Sanofi inaugure en France sa nouvelle unité d’excellence R&D Vaccins

Sanofi inaugure en France sa nouvelle unité d’excellence R&D Vaccins Paris, 18 avril 2025. Sanofi a inauguré ce jour, à Marcy-l’Etoile (Rhône-Alpes), une nouvelle unité d’excellence de R&D...
April 18, 2025 07:45 ET | Source: Research and Markets

Branded Generics Market Size, Share, Trends, Opportunity, and Forecast, 2020-2024 & 2025-2030F

Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- "Branded Generics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ResearchAndMarkets.com's...
April 17, 2025 13:50 ET | Source: CMI

Typhoid Fever Vaccines Market to Hit $884.8 Mn, Globally, by 2030 at 12.2% CAGR: Coherent Market Insights

Burlingame, CA, April 17, 2025 (GLOBE NEWSWIRE) -- Coherent Market Insights published a report, titled, " Typhoid Fever Vaccines Market, by Vaccine Type (Live Attenuated Vaccine, Capsular...
April 17, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Infusion Pumps Market to Soar at a CAGR of ~10% by 2032, Owing to the Advancements in Technology and Increased Demand in Healthcare | DelveInsight

New York, USA, April 17, 2025 (GLOBE NEWSWIRE) -- Infusion Pumps Market to Soar at a CAGR of ~10% by 2032, Owing to the Advancements in Technology and Increased Demand in Healthcare | DelveInsight ...
April 17, 2025 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated...
April 17, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical...